Choroidal neovascularisation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:55 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Choroidal neovascularisation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-faricimab-and-ranibizumab-in-patients-with-choroidal-neovascularization-caused-by-pathologic-myopia/ Thu, 07 May 2026 05:47:10 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-faricimab-and-ranibizumab-in-patients-with-choroidal-neovascularization-caused-by-pathologic-myopia/ This study is for choroidal neovascularization secondary to pathologic myopia, a serious eye problem in which abnormal blood vessels grow under the retina, the light-sensitive layer at the back of the eye. The trial is testing faricimab and comparing it with ranibizumab to see which treatment works better and how safe it is.

Both medicines are given as intravitreal injections, which means they are injected into the eye. In the study, treatment is given over time, and the eye is checked during the study visits to see how the condition changes and whether more than one injection is needed. The purpose of the study is to find out whether faricimab can help improve vision and control the eye disease as well as or better than ranibizumab.

]]> Study on the Use of SB11 Pre-Filled Syringe for Patients with Wet Age-Related Macular Degeneration, Macular Edema from Retinal Vein Occlusion, or Myopic Choroidal Neovascularization https://clinicaltrials.eu/trial/study-on-the-use-of-sb11-pre-filled-syringe-for-patients-with-wet-age-related-macular-degeneration-macular-edema-from-retinal-vein-occlusion-or-myopic-choroidal-neovascularization/ Wed, 29 Apr 2026 15:05:06 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-sb11-pre-filled-syringe-for-patients-with-wet-age-related-macular-degeneration-macular-edema-from-retinal-vein-occlusion-or-myopic-choroidal-neovascularization/ This clinical trial is focused on studying the usability of a new treatment method for eye conditions such as Neovascular Age-Related Macular Degeneration (AMD), Macular Edema Secondary to Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV). The treatment being tested is a solution for injection called Byooviz, which contains the active substance ranibizumab. This study aims to evaluate how well healthcare professionals can use a pre-filled syringe to administer this treatment directly into the eye.

The study involves a single group of participants who will receive a one-time dose of the treatment. Healthcare professionals will follow specific instructions to prepare and give the injection. The main goal is to see how effectively these instructions can be followed. Participants will be monitored for any side effects or changes in their vision over a short period, typically up to a week after the injection.

Throughout the study, the focus will be on the ease of use of the pre-filled syringe and the safety of the treatment. The study will also look at any improvements in vision that may occur after the injection. This research is important for understanding how this new method of delivering ranibizumab can be used in treating these eye conditions effectively and safely.

]]> Study on the Safety and Use of AVT06 (Aflibercept) for Patients with Chorioretinal Vascular Diseases https://clinicaltrials.eu/trial/study-on-the-safety-and-use-of-avt06-aflibercept-for-patients-with-chorioretinal-vascular-diseases/ Wed, 29 Apr 2026 14:26:19 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-use-of-avt06-aflibercept-for-patients-with-chorioretinal-vascular-diseases/ This clinical trial is focused on studying the handling and safety of a treatment called Aflibercept, which is used for various eye conditions. These conditions include neovascular age-related macular degeneration (a type of vision loss in older adults), diabetic macular edema (swelling in the retina due to diabetes), myopic choroidal neovascularization (abnormal blood vessel growth in the eye due to severe nearsightedness), retinal vein occlusion (blockage of veins in the retina), and diabetic retinopathy (damage to the retina caused by diabetes). The treatment is administered as a solution for injection using a pre-filled syringe, referred to as AVT06.

The purpose of this study is to ensure that the AVT06 pre-filled syringe is handled correctly and safely, and to evaluate the safety of the treatment when injected into the eye. Participants in the study will receive the treatment through an injection into the eye, known as intravitreal use. The study will follow participants over a period to monitor the safety and effectiveness of the treatment. There is also an optional extension phase for further observation.

Throughout the study, the focus will be on the successful administration of the treatment and monitoring any side effects related to the eye. The study aims to provide valuable information on the safe use of Aflibercept in treating these eye conditions, helping to improve treatment options for patients with these diseases.

]]>